Literature DB >> 23084596

Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.

Christopher G Willett1, Jennifer Moughan, Elizabeth O'Meara, James M Galvin, Christopher H Crane, Kathryn Winter, Denise Manfredi, Tyvin A Rich, Rachel Rabinovitch, Robert Lustig, Mitchell Machtay, Walter J Curran.   

Abstract

BACKGROUND: This report analyzes the adherence to radiation therapy protocol guidelines in contemporary Radiation Therapy Oncology Group (RTOG) gastrointestinal trials. We aim to provide insight into current standards and compliance of radiation therapy field design and administration.
METHODS: From 1994 to 2006, the Gastrointestinal Cancer Committee of the RTOG initiated and completed 15 phase I-III clinical trials utilizing radiation therapy in the multimodality treatment of gastrointestinal cancers. In each protocol, details for planning and executing radiation therapy were outlined and each protocol contained scoring criteria for these components of radiation therapy, characterized according to per-protocol, variation acceptable and deviation unacceptable. Review of treatment planning and implementation was performed in all studies following therapy completion.
RESULTS: Radiation therapy planning and implementation was reviewed in 2309 of 2312 (99.9%) patients. The mean rate of compliance over all for the 15 protocols was 65% (total of the 2309 analyzed patients). The mean variation acceptable rate was 21% whereas the mean deviation unacceptable rate was 5%. The mean "other" rate (no RT given or incomplete RT due to death, progression or refusal) was 8%. Two of the 15 trials (13%) had deviation unacceptable rates >10%. In four studies incorporating pre-treatment review of radiation therapy planning and treatment, compliance with protocol therapy was enhanced.
CONCLUSIONS: The fidelity of radiation planning and execution detailed in protocol to actual therapy is heterogeneous, with a mean per-protocol rate of 65%. As clinical trials evolve, available technology should permit efficient pre-treatment review processes, thus facilitating compliance to protocol therapy. These analyses should also permit prospective analysis of outcome measures by compliance to therapy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23084596      PMCID: PMC4106147          DOI: 10.1016/j.radonc.2012.09.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

1.  EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility.

Authors:  Alysa Fairchild; Edwin Aird; Paul A Fenton; Vincent Gregoire; Akos Gulyban; Denis Lacombe; Oscar Matzinger; Philip Poortmans; Pascal Ruyskart; Damien C Weber; Coen W Hurkmans
Journal:  Radiother Oncol       Date:  2012-05-23       Impact factor: 6.280

2.  Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).

Authors:  Berthe M P Aleman; Théodore Girinsky; Richard W M van der Maazen; Simon Strijk; Paul Meijnders; Roberto Bortolus; Manouk J J Olofsen-van Acht; Marnix L M Lybeert; Yolande Lievens; Houchingue Eghbali; Evert M Noordijk; Radka Tomsic; Jacobus H Meerwaldt; Philip M P Poortmans; Wilma G J M Smit; Antonella Pinna; Michel Henry-Amar; John M M Raemaekers
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-02       Impact factor: 7.038

3.  Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes.

Authors:  Elena Musat; Philip Poortmans; Walter Van den Bogaert; Henk Struikmans; Alain Fourquet; Harry Bartelink; Carine Kirkove; Volker Budach; Marianne Pierart; Laurence Collette
Journal:  Eur J Cancer       Date:  2007-01-19       Impact factor: 9.162

4.  Processes for quality improvements in radiation oncology clinical trials.

Authors:  T J FitzGerald; Marcia Urie; Kenneth Ulin; Fran Laurie; Jeffrey Yorty; Richard Hanusik; Sandy Kessel; Maryann Bishop Jodoin; Gani Osagie; M Giulia Cicchetti; Richard Pieters; Kathleen McCarten; Nancy Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008       Impact factor: 7.038

5.  Multiinstitutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines.

Authors:  Anke M van Mourik; Paula H M Elkhuizen; Danny Minkema; Joop C Duppen; Corine van Vliet-Vroegindeweij
Journal:  Radiother Oncol       Date:  2010-03-02       Impact factor: 6.280

6.  Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure.

Authors:  Vassilis E Kouloulias; Jean-Francois Bosset; Geertjan van Tienhoven; Bernard J Davis; Marianne Pierart; Philip Poortmans
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

7.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.

Authors:  Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 8.  EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.

Authors:  Oscar Matzinger; Erich Gerber; Zvi Bernstein; Philippe Maingon; Karin Haustermans; Jean François Bosset; Akos Gulyban; Philip Poortmans; Laurence Collette; Abraham Kuten
Journal:  Radiother Oncol       Date:  2009-04-15       Impact factor: 6.280

9.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

10.  Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.

Authors:  Tyvin A Rich; Kathryn Winter; Howard Safran; John P Hoffman; Beth Erickson; Pramila R Anne; Robert J Myerson; Vivian Jm Cline-Burkhardt; Kimberly Perez; Christopher Willett
Journal:  Onco Targets Ther       Date:  2012-08-23       Impact factor: 4.147

View more
  7 in total

1.  Prospective review of radiotherapy trials through implementation of standardized multicentre workflow and IT infrastructure.

Authors:  Sarah Gwynne; Gareth Jones; Rhydian Maggs; David Eaton; Elizabeth Miles; John Staffurth; Lisette Nixon; Ruby Ray; Geraint Lewis; Tom Crosby; Emiliano Spezi
Journal:  Br J Radiol       Date:  2016-06-01       Impact factor: 3.039

2.  The radiotherapy quality assurance gap among phase III cancer clinical trials.

Authors:  Kelsey L Corrigan; Stephen Kry; Rebecca M Howell; Ramez Kouzy; Joseph Abi Jaoude; Roshal R Patel; Anuja Jhingran; Cullen Taniguchi; Albert C Koong; Mary Fran McAleer; Paige Nitsch; Claus Rödel; Emmanouil Fokas; Bruce D Minsky; Prajnan Das; C David Fuller; Ethan B Ludmir
Journal:  Radiother Oncol       Date:  2021-11-25       Impact factor: 6.280

3.  Radiation therapy quality assurance in clinical trials--Global Harmonisation Group.

Authors:  Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

4.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

5.  Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience.

Authors:  Luciana Caravatta; Gabriella Macchia; Gian Carlo Mattiucci; Aldo Sainato; Nunzia L V Cernusco; Giovanna Mantello; Monica Di Tommaso; Marianna Trignani; Antonino De Paoli; Gianni Boz; Maria L Friso; Vincenzo Fusco; Marta Di Nicola; Alessio G Morganti; Domenico Genovesi
Journal:  Radiat Oncol       Date:  2014-09-08       Impact factor: 3.481

6.  A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.

Authors:  Daniel L P Holyoake; Elizabeth Ward; Derek Grose; David McIntosh; David Sebag-Montefiore; Ganesh Radhakrishna; Neel Patel; Michael Silva; Somnath Mukherjee; Victoria Y Strauss; Lang'o Odondi; Emmanouil Fokas; Alan Melcher; Maria A Hawkins
Journal:  BMC Cancer       Date:  2016-09-13       Impact factor: 4.430

7.  FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy.

Authors:  Concetta Piazzese; Elin Evans; Betsan Thomas; John Staffurth; Sarah Gwynne; Emiliano Spezi
Journal:  Br J Radiol       Date:  2021-08-06       Impact factor: 3.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.